One of the abiding philosophies of the Johns Hopkins Division of Rheumatology is that the critical pathway to understanding human autoimmune rheumatic diseases is through the study of large numbers of well-defined patients, followed over time, with the collection of rich phenotypic data, mapping disease trajectory, and where possible, acquiring and storing relevant biological materials from blood and target tissue. This repository of data and samples can then be used to separate heterogeneous diagnostic groups into more homogeneous subgroups, using tools that span the entire spectrum of investigation. This P30 will focus on providing the framework for organizational (oversight, management), operational (recruitment, sampling, processing), measurement and analytical (statistical, computational, and integrative) expertise to enable effective clinical and translational research. The Hopkins RDRCC competitive renewal comprises an Administrative Core (Core A) led by Drs. Rosen and Bingham, and includes 3 scientific Cores: (i) Core B is the Research Management and Patient Integrated Data (RAPID) Core, led by Dr. Bingham; (ii) Core C is the Sample Processing and Immunoassay Research (SPIRE) Core, led by Drs. Casciola-Rosen and Soloski; and Core D is the Data Science Core, led by Dr. Scott Zeger. The Center is structured as a matrix, designed to foster collaborative and synergistic discovery by maximizing access of the diverse research community to data and samples from humans with rheumatic diseases. Core A will promote efficient, interdisciplinary research throughout the research community and Cores, and manage the enrichment program. Core B will facilitate studies on humans with rheumatic diseases, by providing research management and oversight functions, enhancing research integration with the Epic EHR, and enable patient-centered outcome research. Core C will provide assistance with patient sample acquisition, processing, storage and distribution, as well as provision of multiple immunological assays for discovery and validation of biomarkers and disease pathways. Core D will provide highly innovative tools to enable analysis of complex longitudinal data in rheumatic disease patients, particularly with the design and application of Bayesian hierarchical models to identify disease subsets.

Public Health Relevance

This Rheumatic Diseases Resource-based Core Center provides systems and infrastructure to facilitate efficient and significant research on humans with autoimmune rheumatic diseases. The synergies that arise from coupling the diverse and well- resourced research community to the unusually rich collection of prospectively collected data and samples from patients with rheumatic diseases through provision of Core service and expertise provides unprecedented opportunities to enhance and accelerate discovery into the causes, mechanisms, diagnosis, therapy and prevention in these diseases.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1)
Program Officer
Mancini, Marie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Cappelli, Laura C; Gutierrez, Anna Kristina; Baer, Alan N et al. (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43-50
Dein, Eric; Sharfman, William; Kim, Jean et al. (2017) Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition. J Immunother 40:312-314
Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2017) Pain Sensitization is Associated with Disease Activity in Rheumatoid Arthritis Patients: A Cross-Sectional Study. Arthritis Care Res (Hoboken) :
Wangsiricharoen, Sintawat; Ligon, Colin; Gedmintas, Lydia et al. (2017) Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. Arthritis Care Res (Hoboken) 69:449-452
Cappelli, Laura C; Palmer, Judy Lynn; Kremer, Joel et al. (2017) Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Semin Arthritis Rheum 47:165-169
Orbai, Ana-Maria; de Wit, Maarten; Mease, Philip J et al. (2017) Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol 44:1522-1528
Orbai, Ana-Maria; de Wit, Maarten; Mease, Philip et al. (2017) International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 76:673-680
De Biase, Lindsay M; Schuebel, Kornel E; Fusfeld, Zachary H et al. (2017) Local Cues Establish and Maintain Region-Specific Phenotypes of Basal Ganglia Microglia. Neuron 95:341-356.e6
Cappelli, Laura C; Gutierrez, Anna Kristina; Bingham 3rd, Clifton O et al. (2017) Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken) 69:1751-1763
Ogdie, Alexis; de Wit, Maarten; Callis Duffin, Kristina et al. (2017) Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. J Rheumatol 44:697-700

Showing the most recent 10 out of 11 publications